Symbols / SCYX
SCYX Chart
About
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 32.85M |
| Enterprise Value | -2.62M | Income | -25.30M | Sales | 2.93M |
| Book/sh | 0.87 | Cash/sh | 0.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | — |
| P/E | — | Forward P/E | -13.81 | PEG | — |
| P/S | 11.20 | P/B | 0.90 | P/C | — |
| EV/EBITDA | — | EV/Sales | -0.89 | Quick Ratio | 5.66 |
| Current Ratio | 5.75 | Debt/Eq | 6.27 | LT Debt/Eq | — |
| EPS (ttm) | -0.51 | EPS next Y | -0.06 | EPS Growth | — |
| Revenue Growth | -49.40% | Earnings | 2026-03-18 | ROA | -28.85% |
| ROE | -53.29% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -25.16% | Profit Margin | 0.00% | Shs Outstand | 41.97M |
| Shs Float | 35.28M | Short Float | 3.35% | Short Ratio | 2.36 |
| Short Interest | — | 52W High | 1.31 | 52W Low | 0.56 |
| Beta | 1.34 | Avg Volume | 418.78K | Volume | 409.08K |
| Target Price | $3.67 | Recom | None | Prev Close | $0.79 |
| Price | $0.78 | Change | -0.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.67
Mean price target
2. Current target
$0.78
Latest analyst target
3. DCF / Fair value
$-9.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.78
Low
$3.00
High
$4.00
Mean
$3.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-28 | main | Guggenheim | Buy → Buy | $3 |
| 2024-04-01 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2023-08-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $15 |
| 2023-04-03 | main | Guggenheim | — → Buy | $9 |
| 2023-04-03 | reit | Ladenburg Thalmann | — → Buy | $15 |
| 2023-03-01 | init | Guggenheim | — → Buy | $8 |
| 2022-05-13 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2022-03-31 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2021-06-07 | main | Aegis Capital | — → Buy | $35 |
| 2021-04-12 | main | Aegis Capital | — → Buy | $40 |
| 2021-01-22 | init | Guggenheim | — → Buy | $25 |
| 2021-01-06 | init | Cantor Fitzgerald | — → Overweight | $30 |
| 2020-12-28 | reit | HC Wainwright & Co. | — → Buy | $20 |
| 2020-04-23 | main | Aegis Capital | — → Buy | $5 |
| 2018-10-16 | main | Maxim Group | Buy → Buy | $4 |
| 2018-06-27 | init | Maxim Group | — → Buy | $6 |
| 2018-05-24 | init | Ladenburg Thalmann | — → Buy | $9 |
| 2018-04-10 | init | Seaport Global | — → Buy | $4 |
| 2017-10-24 | init | Guggenheim | — → Buy | $6 |
| 2017-01-31 | init | Aegis Capital | — → Buy | $7 |
- Scynexis (NASDAQ: SCYX) fungerps program included in $7M NIH CETR grant - Stock Titan Mon, 17 Nov 2025 08
- Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation - Yahoo Finance Mon, 10 Nov 2025 08
- Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - simplywall.st Fri, 23 Jan 2026 08
- New Analyst Forecast: $SCYX Given 'Buy' Rating - Quiver Quantitative ue, 28 Oct 2025 07
- Can SCYX maintain sales growth - July 2025 Highlights & Low Risk High Reward Ideas - mfd.ru Sun, 22 Feb 2026 14
- SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks hu, 26 Jun 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Sun, 14 Jan 2024 00
- SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan Wed, 19 Nov 2025 08
- SCYNEXIS Secures $24.8 Million Payment from GSK and Advances SCY-247 Development Plans Amid Phase 3 Study Termination | SCYX Stock News - Quiver Quantitative Wed, 05 Nov 2025 08
- SCYX Achieves Key Milestones and Exceeds Q3 Revenue Expectations - GuruFocus Wed, 05 Nov 2025 08
- Decliners Report: Is SCYX undervalued by DCF analysis - 2025 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn Sat, 21 Feb 2026 23
- SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247 - Yahoo Finance Fri, 24 Oct 2025 07
- SCYNEXIS and GSK Amend License Agreement - TipRanks Wed, 15 Oct 2025 07
- Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX) - Seeking Alpha ue, 02 Apr 2024 07
- SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties - Quiver Quantitative Wed, 19 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 391333 | — | — | Stock Award(Grant) at price 0.00 per share. | ANGULO GONZALEZ DAVID | Chief Executive Officer | — | 2026-01-29 00:00:00 | D |
| 1 | 129833 | — | — | Stock Award(Grant) at price 0.00 per share. | SUKENICK SCOTT A. J.D. | Officer | — | 2026-01-29 00:00:00 | D |
| 2 | 129833 | — | — | Stock Award(Grant) at price 0.00 per share. | MACLEOD IVOR | Chief Financial Officer | — | 2026-01-29 00:00:00 | D |
| 3 | 32500 | 24700 | — | Stock Award(Grant) at price 0.76 per share. | ANGULO GONZALEZ DAVID | Chief Executive Officer | — | 2025-10-17 00:00:00 | D |
| 4 | 23000 | — | — | Stock Award(Grant) at price 0.00 per share. | ANIDO ARMANDO | Director | — | 2025-06-26 00:00:00 | D |
| 5 | 23000 | — | — | Stock Award(Grant) at price 0.00 per share. | HASTINGS DAVID C | Director | — | 2025-06-26 00:00:00 | D |
| 6 | 23000 | — | — | Stock Award(Grant) at price 0.00 per share. | HANHAM ANN F | Director | — | 2025-06-26 00:00:00 | D |
| 7 | 23000 | — | — | Stock Award(Grant) at price 0.00 per share. | MACDONALD GUY | Director | — | 2025-06-26 00:00:00 | D |
| 8 | 23000 | — | — | Stock Award(Grant) at price 0.00 per share. | GILMAN STEVEN C | Director | — | 2025-06-26 00:00:00 | D |
| 9 | 23000 | — | — | Stock Award(Grant) at price 0.00 per share. | TINMOUTH BRIAN PHILIPPE | Director | — | 2025-06-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 2.94M | -3.32K | 1.64M | 2.39M |
| TaxRateForCalcs | 0.21 | 0.00 | 0.07 | 0.08 |
| NormalizedEBITDA | -34.32M | 74.21M | -85.32M | -61.73M |
| TotalUnusualItems | 14.01M | -3.32M | 23.62M | 28.81M |
| TotalUnusualItemsExcludingGoodwill | 14.01M | -3.32M | 23.62M | 28.81M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.29M | 67.04M | -62.81M | -32.87M |
| ReconciledDepreciation | 0.00 | 580.00K | 606.00K | 379.00K |
| ReconciledCostOfRevenue | 0.00 | 15.62M | 628.00K | 312.00K |
| EBITDA | -20.31M | 70.89M | -61.70M | -32.91M |
| EBIT | -20.31M | 70.31M | -62.31M | -33.29M |
| NetInterestIncome | 1.74M | -2.17M | -5.37M | -3.94M |
| InterestExpense | 828.00K | 3.13M | 5.20M | 2.66M |
| InterestIncome | 4.29M | 3.95M | 1.42M | 24.00K |
| NormalizedIncome | -32.35M | 70.36M | -84.78M | -59.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.29M | 67.04M | -62.81M | -32.87M |
| TotalExpenses | 40.86M | 67.47M | 90.85M | 74.00M |
| TotalOperatingIncomeAsReported | -37.12M | 72.67M | -85.76M | -60.84M |
| DilutedAverageShares | 48.51M | 48.39M | 42.61M | 26.38M |
| BasicAverageShares | 48.51M | 47.85M | 42.61M | 26.38M |
| DilutedEPS | -0.44 | 1.39 | -1.47 | -1.25 |
| BasicEPS | -0.44 | 1.40 | -1.47 | -1.25 |
| DilutedNIAvailtoComStockholders | -21.29M | 67.04M | -62.81M | -32.87M |
| NetIncomeCommonStockholders | -21.29M | 67.04M | -62.81M | -32.87M |
| NetIncome | -21.29M | 67.04M | -62.81M | -32.87M |
| NetIncomeIncludingNoncontrollingInterests | -21.29M | 67.04M | -62.81M | -32.87M |
| NetIncomeContinuousOperations | -21.29M | 67.04M | -62.81M | -32.87M |
| TaxProvision | 151.00K | 138.00K | -4.70M | -3.09M |
| PretaxIncome | -21.14M | 67.18M | -67.51M | -35.95M |
| OtherIncomeExpense | 14.24M | -3.32M | 23.62M | 28.82M |
| OtherNonOperatingIncomeExpenses | 235.00K | 3.00K | 13.00K | |
| SpecialIncomeCharges | 0.00 | -2.73M | ||
| OtherSpecialCharges | 2.73M | |||
| GainOnSaleOfSecurity | 14.01M | -3.32M | 23.62M | 31.54M |
| NetNonOperatingInterestIncomeExpense | 1.74M | -2.17M | -5.37M | -3.94M |
| TotalOtherFinanceCost | 1.73M | 2.99M | 1.59M | 1.30M |
| InterestExpenseNonOperating | 828.00K | 3.13M | 5.20M | 2.66M |
| InterestIncomeNonOperating | 4.29M | 3.95M | 1.42M | 24.00K |
| OperatingIncome | -37.12M | 72.67M | -85.76M | -60.84M |
| OperatingExpense | 40.86M | 51.85M | 90.22M | 73.69M |
| OtherTaxes | -13.00K | |||
| ResearchAndDevelopment | 26.41M | 30.93M | 27.26M | 23.77M |
| SellingGeneralAndAdministration | 14.46M | 20.92M | 62.96M | 49.92M |
| GrossProfit | 3.75M | 124.52M | 4.46M | 12.85M |
| CostOfRevenue | 0.00 | 15.62M | 628.00K | 312.00K |
| TotalRevenue | 3.75M | 140.14M | 5.09M | 13.16M |
| OperatingRevenue | 3.75M | 140.14M | 5.09M | 13.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 37.97M | 37.21M | 32.68M | 28.71M |
| ShareIssued | 37.97M | 37.21M | 32.68M | 28.71M |
| TotalDebt | 16.27M | 15.08M | 48.60M | 43.63M |
| TangibleBookValue | 55.08M | 72.96M | 2.83M | 40.20M |
| InvestedCapital | 68.77M | 85.12M | 48.63M | 81.61M |
| WorkingCapital | 48.08M | 85.81M | 61.44M | 95.76M |
| NetTangibleAssets | 55.08M | 72.96M | 2.83M | 40.20M |
| CapitalLeaseObligations | 2.58M | 2.92M | 3.20M | 3.27M |
| CommonStockEquity | 55.08M | 72.96M | 3.23M | 41.26M |
| TotalCapitalization | 55.08M | 85.12M | 48.63M | 81.61M |
| TotalEquityGrossMinorityInterest | 55.08M | 72.96M | 3.23M | 41.26M |
| StockholdersEquity | 55.08M | 72.96M | 3.23M | 41.26M |
| RetainedEarnings | -376.54M | -355.25M | -422.29M | -359.48M |
| AdditionalPaidInCapital | 431.57M | 428.17M | 425.49M | 400.70M |
| CapitalStock | 41.00K | 40.00K | 36.00K | 32.00K |
| CommonStock | 41.00K | 40.00K | 36.00K | 32.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 35.57M | 55.45M | 84.58M | 78.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 11.47M | 39.15M | 66.96M | 64.96M |
| OtherNonCurrentLiabilities | 3.35M | |||
| DerivativeProductLiabilities | 8.00M | 21.68M | 18.64M | 18.06M |
| NonCurrentDeferredLiabilities | 1.29M | 2.73M | 0.00 | |
| NonCurrentDeferredRevenue | 1.29M | 2.73M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 2.17M | 14.74M | 48.31M | 43.56M |
| LongTermCapitalLeaseObligation | 2.17M | 2.58M | 2.92M | 3.20M |
| LongTermDebt | 12.16M | 45.39M | 40.35M | |
| CurrentLiabilities | 24.10M | 16.30M | 17.62M | 13.62M |
| OtherCurrentLiabilities | 130.00K | 5.77M | ||
| CurrentDeferredLiabilities | 1.64M | 1.19M | 0.00 | |
| CurrentDeferredRevenue | 1.64M | 1.19M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 14.10M | 340.00K | 282.00K | 70.00K |
| CurrentCapitalLeaseObligation | 407.00K | 340.00K | 282.00K | 70.00K |
| CurrentDebt | 13.69M | |||
| OtherCurrentBorrowings | 13.69M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.76M | 1.69M | 2.32M | 2.01M |
| PayablesAndAccruedExpenses | 6.60M | 12.95M | 9.25M | 11.53M |
| CurrentAccruedExpenses | 2.03M | 5.80M | 3.31M | 3.69M |
| Payables | 4.57M | 7.15M | 5.94M | 7.85M |
| AccountsPayable | 4.57M | 7.15M | 5.94M | 7.85M |
| TotalAssets | 90.64M | 128.41M | 87.81M | 119.84M |
| TotalNonCurrentAssets | 18.46M | 26.30M | 8.75M | 10.46M |
| OtherNonCurrentAssets | 109.00K | 163.00K | 5.67M | 6.45M |
| NonCurrentDeferredAssets | 417.00K | 175.00K | 73.00K | 150.00K |
| InvestmentsAndAdvances | 15.85M | 23.59M | 0.00 | |
| InvestmentinFinancialAssets | 15.85M | 23.59M | 0.00 | |
| HeldToMaturitySecurities | 15.85M | 23.59M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 408.00K | 1.06M | |
| NetPPE | 2.09M | 2.36M | 2.59M | 2.80M |
| AccumulatedDepreciation | -467.00K | |||
| GrossPPE | 2.09M | 2.36M | 2.59M | 2.80M |
| OtherProperties | 2.09M | 2.36M | 2.59M | 2.80M |
| MachineryFurnitureEquipment | 482.00K | |||
| CurrentAssets | 72.18M | 102.12M | 79.06M | 109.38M |
| OtherCurrentAssets | 1.23M | 4.91M | 62.00K | 4.00K |
| RestrictedCash | 435.00K | 380.00K | 55.00K | 0.00 |
| PrepaidAssets | 950.00K | 642.00K | 2.44M | 3.56M |
| Inventory | 0.00 | 899.00K | 463.00K | |
| FinishedGoods | 0.00 | 24.00K | 127.00K | |
| WorkInProcess | 0.00 | 610.00K | 3.00K | |
| RawMaterials | 0.00 | 265.00K | 333.00K | |
| Receivables | 10.26M | 21.83M | 2.10M | 861.00K |
| OtherReceivables | 10.26M | 21.83M | ||
| AccountsReceivable | 0.00 | 2.10M | 861.00K | |
| CashCashEquivalentsAndShortTermInvestments | 59.30M | 74.36M | 73.50M | 104.48M |
| OtherShortTermInvestments | 43.25M | 40.31M | 27.69M | 0.00 |
| CashAndCashEquivalents | 16.05M | 34.05M | 45.81M | 104.48M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.01M | 60.16M | -79.89M | -55.73M |
| RepaymentOfDebt | 0.00 | -36.65M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 5.00M | 30.00M | |
| IssuanceOfCapitalStock | 0.00 | 18.00K | 47.25M | 38.56M |
| CapitalExpenditure | -9.00K | -1.17M | ||
| InterestPaidSupplementalData | 840.00K | 3.25M | 5.19M | 2.25M |
| EndCashPosition | 16.59M | 34.59M | 46.03M | 104.70M |
| BeginningCashPosition | 34.59M | 46.03M | 104.70M | 93.31M |
| ChangesInCash | -18.00M | -11.44M | -58.67M | 11.39M |
| FinancingCashFlow | -139.00K | -36.72M | 48.60M | 67.12M |
| CashFlowFromContinuingFinancingActivities | -139.00K | -36.72M | 48.60M | 67.12M |
| NetOtherFinancingCharges | -195.00K | -135.00K | -3.66M | -1.46M |
| ProceedsFromStockOptionExercised | 56.00K | 42.00K | 18.00K | 22.00K |
| NetCommonStockIssuance | 0.00 | 18.00K | 47.25M | 38.56M |
| CommonStockIssuance | 0.00 | 18.00K | 47.25M | 38.56M |
| NetIssuancePaymentsOfDebt | 0.00 | -36.65M | 5.00M | 30.00M |
| NetLongTermDebtIssuance | 0.00 | -36.65M | 5.00M | 30.00M |
| LongTermDebtPayments | 0.00 | -36.65M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 5.00M | 30.00M | |
| InvestingCashFlow | 6.15M | -34.88M | -27.39M | -1.17M |
| CashFlowFromContinuingInvestingActivities | 6.15M | -34.88M | -27.39M | -1.17M |
| NetInvestmentPurchaseAndSale | 6.15M | -34.88M | -27.38M | 0.00 |
| SaleOfInvestment | 42.57M | 50.60M | 0.00 | 0.00 |
| PurchaseOfInvestment | -36.42M | -85.48M | -27.38M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -9.00K | -1.17M | |
| PurchaseOfIntangibles | 0.00 | -9.00K | -1.17M | |
| NetPPEPurchaseAndSale | 0.00 | |||
| PurchaseOfPPE | 0.00 | |||
| OperatingCashFlow | -24.01M | 60.16M | -79.88M | -54.56M |
| CashFlowFromContinuingOperatingActivities | -24.01M | 60.16M | -79.88M | -54.56M |
| ChangeInWorkingCapital | 7.28M | -30.64M | 764.00K | 3.15M |
| ChangeInOtherWorkingCapital | -979.00K | 3.92M | ||
| ChangeInOtherCurrentLiabilities | -339.00K | -6.05M | 2.35M | |
| ChangeInPayablesAndAccruedExpense | -6.35M | 3.04M | -1.55M | 7.70M |
| ChangeInAccruedExpense | -3.70M | 1.87M | -70.00K | 4.94M |
| ChangeInPayable | -2.65M | 1.17M | -1.48M | 2.76M |
| ChangeInAccountPayable | -2.65M | 1.17M | -1.48M | 2.76M |
| ChangeInPrepaidAssets | 3.39M | -2.97M | 1.64M | 1.60M |
| ChangeInInventory | 0.00 | -8.85M | -436.00K | -5.29M |
| ChangeInReceivables | 11.56M | -19.73M | -1.24M | -861.00K |
| ChangesInAccountReceivables | 0.00 | 2.10M | -1.24M | -861.00K |
| OtherNonCashItems | 2.00M | 3.22M | 1.80M | 1.50M |
| StockBasedCompensation | 3.35M | 2.62M | 3.69M | 2.09M |
| AssetImpairmentCharge | 0.00 | 15.35M | 0.00 | |
| AmortizationOfSecurities | -1.34M | -1.34M | -309.00K | 0.00 |
| DepreciationAmortizationDepletion | 0.00 | 580.00K | 606.00K | 379.00K |
| DepreciationAndAmortization | 0.00 | 580.00K | 606.00K | 379.00K |
| OperatingGainsLosses | -14.01M | 3.32M | -23.62M | -28.81M |
| GainLossOnInvestmentSecurities | -14.01M | 3.32M | -23.62M | -31.54M |
| NetIncomeFromContinuingOperations | -21.29M | 67.04M | -62.81M | -32.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SCYX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|